Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
DM199 for Pregnancy Complications
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 120
- Registration Number
- NCT06875141
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- Conditions
- Acute StrokeStrokeIschemic Stroke
- Interventions
- Drug: Recombinant human tissue kallikreinOther: Placebo for DM199 Solution for Injection
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 728
- Registration Number
- NCT05065216
- Locations
- 🇺🇸
Gulf Health Hospitals d/b/a Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Glendale Adventist Medical Center d/b/a Adventist Health Glendale, Glendale, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 79
- Registration Number
- NCT04123613
- Locations
- 🇺🇸
Aventiv Research, Mesa, Arizona, United States
🇺🇸Amcis Research Center, Granada Hills, California, United States
🇺🇸IMD Clinical Trials Inc, Los Angeles, California, United States
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
- Conditions
- Chronic Kidney DiseaseChronic Kidney Disease, Stage 3 (Moderate)Chronic Kidney Disease, Stage 4 (Severe)Diabetes
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03795389
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center Inc, Orlando, Florida, United States
🇺🇸Prism Research, Saint Paul, Minnesota, United States
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: PlaceboDrug: Recombinant human tissue kallikrein
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 92
- Registration Number
- NCT03290560
- Locations
- 🇦🇺
Lismore Base Hospital, Lismore, New South Wales, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺John Hunter Hospital, New Lambton Heights, New South Wales, Australia
- Prev
- 1
- 2
- Next